all
Bayer Predicts Falls in Pharma Sales, Novo Cuts Wegovy Price and More
This week’s report covers Bayer’s prolonged sales slump, a price cut for self-pay Wegovy patients and much more.
Medicare Diabetes Drug Spending, Madrigal’s Exceptional Launch and More
This edition covers the implications of a jump in Medicare Part D spending on diabetes drugs, news that Madrigal Pharmaceuticals’ launch is going “exceptionally well” and much more.
BridgeBio Makes Fast Launch, Pfizer Axes Gene Therapy and More
This week’s edition covers BridgeBio’s fast launch, Pfizer’s continued pullback from gene therapies and the bargain basement buyout of bluebird bio.
Merck KGaA Makes M&A Move, Big Pharmas Win FDA Approvals and More
This week’s edition covers Merck KGaA’s moves to buy a biotech, approvals for GSK, Roche and Pfizer and an update on the launch of Eisai and Biogen’s Leqembi.
BMS Plots $2B in Cuts, Lilly Talks Obesity Sales ‘Turbulence’ and More
The past week brought news of more cuts at Bristol Myers Squibb, quarterly earnings at companies including Eli Lilly, GSK and Pfizer and a legal row between Dupixent partners Regeneron and Sanofi.
CMS Outlines Tweaks to Price Negotiations, Vertex Wins FDA Approval and More
The past week brought an early look at how political change may affect price negotiations, FDA approval of a Vertex drug that could deliver big blockbuster sales and much more.
J&J Makes Spravato a Blockbuster, GLP-1s Show Alzheimer’s Promise and More
The past week was rich with neuroscience news, with Johnson & Johnson reporting a jump in sales of its depression drug, Teva Pharmaceuticals receiving a black box safety warning for a multiple sclerosis treatment and much more.
J&J Inks $15B Buyout, Lilly’s Sales Fall Short and Moderna Plans More Cuts
J.P. Morgan Healthcare Conference week brought a flurry of news, including a $14.6 billion takeover by Johnson & Johnson and lackluster sales updates from Eli Lilly, Moderna and Regeneron.
Drug Pricing Trends, RSV Vaccine Risks and an ‘Anticompetitive Scheme’
This week brought analyses of drug pricing trends, predictions of another major market for GLP-1 drugs and much more.
Lilly Wins Zepbound Approval, Drugmakers Raise Prices and More
Another batch of FDA approvals arrived over the new year period, bringing news of authorizations that could unlock Medicare coverage for Eli Lilly’s GLP-1 blockbuster Zepbound and open a new front in Bristol Myers Squibb’s long-running fight for the immuno-oncology market.
FDA Rejects AstraZeneca, J&J filings, US Drug Spending Climbs and More
As the end of 2024 came into view, the FDA rattled off a series of authorization decisions, approving treatments from companies including Ionis Pharmaceuticals and Neurocrine Biosciences and rejecting applications from AstraZeneca, Johnson & Johnson and Zealand Pharma.
Pharmas Share Bumper Batch of Cancer Data, ICER Names Price Hikes and More
The past week delivered a bumper crop of late-phase cancer data as Eli Lilly, GSK, Johnson & Johnson, Pfizer and other drug developers used oncology events to share potentially practice-changing evidence on their products and prospects.
Zepbound Beats Wegovy, Pharma CEOs Meet Trump and Novo Cuts Insulin Prices
This week brought news of the winner of a head-to-head obesity trial, a meeting between pharma CEOs and the President-elect and much more.
CMS Moves to Cover Obesity Drugs, Mooted Ad Ban Worries Analysts and More
Thanksgiving week brought updates on preparations for Donald Trump’s administration, Phase III wins for AstraZeneca and Merck and more.
Trump Picks FDA Chief, Merck Advances Subq Keytruda and More
This week brought updates on President-elect Donald Trump’s healthcare plans, rejections and approvals at the FDA and an increase in Novartis’ medium-term growth outlook.
Trumps Picks RFK Jr. for HHS role, Drugmakers Challenge 340B and More
Political events made the headlines over the past week as the incoming U.S. government began to take shape and drugmakers challenged resistance to new approaches to 340B rebates.
Novo Nordisk Sales Fall Short, Gilead Beats Expectations and More
More earnings reports crossed the wires this week, shedding light on the evolving market for GLP-1 drugs and the competitive dynamics in other therapeutic areas.
Lilly’s GLP-1 Sales Fall Short, Pfizer Beats Expectations and More
This week brings a bumper crop of earnings news, with a setback to Eli Lilly contrasting with beat-and-raise quarters at multiple drugmakers including Pfizer.
Pfizer Investor Makes Demands, Senators Probe Sales Platforms and More
This edition features updates on Pfizer’s row with an activist investor, the compounding of GLP-1 drugs and the potential availability and impact of a Eylea biosimilar.
J&J Posts Earnings Beat, FDA Delays Amgen Decision and More
Over the past week, Johnson & Johnson got pharma earnings season underway, the FDA delayed two regulatory decisions and AbbVie won approval at the third attempt.
Most Popular
Bayer Predicts Falls in Pharma Sales, Novo Cuts Wegovy Price and More
This week’s report covers Bayer’s prolonged sales slump, a price cut for self-pay Wegovy patients and much more.
Medicare Diabetes Drug Spending, Madrigal’s Exceptional Launch and More
This edition covers the implications of a jump in Medicare Part D spending on diabetes drugs, news that Madrigal Pharmaceuticals’ launch is going “exceptionally well” and much more.
BridgeBio Makes Fast Launch, Pfizer Axes Gene Therapy and More
This week’s edition covers BridgeBio’s fast launch, Pfizer’s continued pullback from gene therapies and the bargain basement buyout of bluebird bio.
Merck KGaA Makes M&A Move, Big Pharmas Win FDA Approvals and More
This week’s edition covers Merck KGaA’s moves to buy a biotech, approvals for GSK, Roche and Pfizer and an update on the launch of Eisai and Biogen’s Leqembi.
Become a MedReps member
Become a MedReps member for unlimited access to medical sales jobs, career advice and salary information. Kickstart your career in medical sales today.
Subscribe To Our Newsletter
By subscribing to our mailing list, you agree to receive marketing communications, updates, and relevant information about our services and offers. We are committed to respecting your preferences, and you can unsubscribe from these communications at any time by following the link provided in our emails or contacting our support team. Your privacy is important to us, and we ensure that your information is safe and handled in accordance with MedReps' privacy policy.
MEMBERS
- Login
- Membership
- Search Jobs
- Career Advice
- Medical Sales Salaries
- FAQ